Screening of Hub Genes in Hepatocellular Carcinoma Based on Network Analysis and Machine Learning

Yu Zhang, Yongfang Xie, Xiaorong Huang, Langlang Zhang, and Kunxian Shu

School of Bioinformatics, Chongqing University of Posts and Telecommunications, 400000, China

Correspondence should be addressed to Yongfang Xie; xyf1688@126.com and Kunxian Shu; shukx@cqupt.edu.cn

Received 14 July 2022; Revised 11 October 2022; Accepted 1 November 2022; Published 28 November 2022

Academic Editor: Huiling Chen

Copyright © 2022 Yu Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Hepatocellular carcinoma (HC) is the fifth common cancer worldwide, and it requires effective diagnosis and treatment to prevent aggressive metastasis. The purpose of this study was to construct a machine learning-based diagnostic model for the diagnosis of liver cancer. Using weighted correlation network analysis (WGCNA), univariate analysis, and Lasso-Cox regression analysis, protein-protein interactions network analysis is used to construct gene networks from transcriptome data of hepatocellular carcinoma patients and find hub genes for machine learning. The five models, including gradient boosting, random forest, support vector machine, logistic regression, and integrated learning, were to identify a multigene prediction model of patients. Immunological assessment, TP53 gene mutation and promoter methylation level analysis, and KEGG pathway analysis were performed on these groups. Potential drug molecular targets for the corresponding hepatocellular carcinomas were obtained by molecular docking for analysis, resulting in the screening of 2 modules that may be relevant to the survival of hepatocellular carcinoma patients, and the construction of 5 diagnostic models and multiple interaction networks. The modes of action of drug-molecule interactions that may be effective against hepatocellular carcinoma core genes CCNA2, CCNB1, and CDK1 were investigated. This study is expected to provide research ideas for early diagnosis of hepatocellular carcinoma.

1. Introduction

Liver cancer is one of the most common cancers worldwide. The incidence of liver cancer accounts for 8.2% of total cancer cases and 4.7% of total cancer deaths. In some regions, the incidence rate is still increasing. Despite significant improvements in the diagnosis and treatment of liver cancer, the long-term prognosis remains poor, and liver cancer remains an important global clinical challenge [1, 2]. Therefore, the development of more sensitive diagnostic methods, the use of new biomarkers, and the construction of effective prognostic models are important to improve the survival time of patients.

Image-based algorithms drive the diagnosis of disease [3, 4]. HCC can be diagnosed based on imaging features alone, and the noninvasive nature and wide availability have led many HCC guidelines to recommend image-based diagnosis [5]. Several studies have shown good results in classifying liver cancer images by using a machine learning approach [6, 7]. Serum α-fetoprotein (AFP) has been widely used as a predictive and prognostic biomarker for HCC, but the sensitivity of AFP for detecting early stage HCC is limited [8, 9]. The construction of machine learning models by some candidate markers such as cell-free DNA (cfDNA) provides room for improvement in the diagnosis of HCC [10]. In recent years, the use of other samples for prediction has also shown good promise [11, 12]. However, the selection of these characteristics does not explain well the mechanism of hepatocarcinogenesis and prognostic therapies at the genetic level. RNA sequencing (RNA-seq) can reveal gene fusions, splice variants, mutations/insertions deletions, and differential gene expression, thus providing a more complete genetic map than DNA sequencing [13]. Some current statistical analyses of the hepatocellular carcinoma transcriptome suffer from the problem of focusing only on statistical results and detaching from the biological context. Machine learning is better able to deal with complex nonlinear relationships in the data than some conventional
statistical tools; however, part of the models lacks explanatory power [14].

Weighted correlation network analysis (WGCNA) aggregates genes with similar expression patterns in the same genetic module and identifies relationships between gene modules and phenotypes to identify potential candidate biomarkers or novel therapeutic targets [15]. The competing endogenous RNA (ceRNA) hypothesis addresses a complex posttranscriptional regulatory network. When two transcripts contain the same miRNA response element (MRE), they can compete with a shared miRNA. This means that the upregulation of one transcript leads to the segregation of more copies of the shared miRNA, which reduces the expression of the other transcript and vice versa [16].

In this study, we screened genes with survival and other indicators by WGCNA and used univariate—Lasso—multiple Cox regression analysis and survival analysis and protein—protein interactions (PPI) to screen for signature genes. Training was performed using random forest, gradient boosting, support vector machine, logistic regression, and integrated learning. The gene characteristics are also explained by ceRNA network, pathway enrichment and integrated learning. The gene characteristics are also explained by ceRNA network, pathway enrichment and integrated learning.

2.3. Construction of Coexpressed Gene Networks Based on WGCNA. WGCNA is an analysis method to identify gene coexpression networks based on topological overlap. The final input of 6,500 genes was made by descending order of the expression values of the dataset. WGCNA was then used to construct coexpression networks of differential genes. Coexpression gene networks were created with a soft threshold of minimum value of $R^2 > 0.9$ to cluster genes with high correlation into the same module. Correlations between modules and clinical data were calculated to screen for modules associated with survival time and other diagnosis or diagnosis of HCC. Finally, correlated mRNA and lncRNA were obtained.

2.4. Construction of RNA Network in Hepatocellular Carcinoma. The interactions between lncRNA and miRNA and miRNA and mRNA in the WGCNA module were predicted using ENCORI (http://starbase.sysu.edu.cn/index.php?version3.0). The predicted miRNAs intersected with the differential miRNAs in TCGA. In addition, the predicted RBPs that interact with the lncRNAs and miRNAs in the module were taken to intersect and merge. Finally, data on the interactions between these RBPs and miRNAs in different organs and cancer types were retrieved. These networks were visualized by Cytoscape (3.7.2). Finally, we obtained lncRNA-miRNA-mRNA, lncRNA-RBP-mRNA, and RBP-mRNA-tissue-disease networks.

We used the database search tool for retrieval of interacting genes/proteins (STRING) (https://www.string-db.org/) to evaluate protein—protein interactions (PPI) information and Cytoscape (3.7.2) for visualization. The R package “clusterProfiler” was used to perform Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses [17]. GSEA (version 4.1.0) was used for gene set enrichment analysis (GSEA) [18], where we defined enrichment markers as FDR < 0.25, NOM $p$ value <0.05, and |NES| > 1.

2.5. Construction and Validation. To minimize the risk of overfitting, Lasso-penalized Cox regression analysis was applied to construct the prognostic model. The Lasso algorithm was used for variable selection and shrinkage using the “glmnet” R package. Patients were divided into high-risk and low-risk groups based on the median risk score. The risk score was calculated as follows: $\text{riskscore} = \sum (\text{coeficienti} \times \text{expression of signature gene})$. Differences in OS time between risk groups were analyzed using Kaplan-Meier (KM) survival analysis and log-rank test.

2.6. HCC Diagnostic Model Construction and Core Gene Screening. Training and test sets for model construction were divided from the dataset generated by combining the TCGA and GSE76427 datasets from the GPL10558 platform. To validate the stability of the model, we used the GSE102079 dataset from the GPL570 platform as the validation set. The relevant clinical characterization data were downloaded through UCSC Xena (http://xena.ucsc.edu/). After screening, we retained 294 samples of the lncRNA and mRNA dataset (including 50 normal samples and 244 tumor samples). In machine learning, the training data is GSE102079 (including 105 normal samples and 152 tumor samples). The RNA-seq data associated with HCC were downloaded from TCGA. There were 424 lncRNA and mRNA samples, including 50 normal samples and 374 tumor samples. And 425 miRNA samples were also downloaded, including 50 normal samples and 375 tumor samples. The relevant clinical characterization data were downloaded through UCSC Xena.

After screening, we retained 294 samples of the lncRNA and mRNA dataset (including 50 normal samples and 244 tumor samples). In machine learning, the training data is GSE102079 (including 105 normal samples and 152 tumor samples) from the GPL570 platform.
Figure 1: Overall flowchart of this study.

Figure 2: Differential analysis of data in the TCGA-LIHC samples. The volcano map for differential genes is presented, in which the x-axis represents $-\log_{10}$ (FDR), and the y-axis represents logFC. Each dot in the map represents a gene, where the red dots represent the upregulated genes in HCC, and the blue dots represent the downregulated genes in HCC: (a) lncRNA, (b) mRNA, and (c) miRNA.
Figure 3: GO and KEGG pathway analyses of upregulated and downregulated differential mRNA. (a) GO biological process (GO-BP) of upregulated differential mRNA. (b) GO cellular component (GO-CC) of upregulated differential mRNA. (c) GO molecular function (GO-MF) of upregulated differential mRNA. (d) KEGG pathway of upregulated differential mRNA. (e) GO-BP of downregulated differential mRNA. (f) GO-CC of downregulated differential mRNA. (g) GO-MF of downregulated differential mRNA. (h) KEGG pathway of downregulated differential mRNA.

Table 1: Univariate Cox regression results.

| Clinical                          | HR      | P       |
|----------------------------------|---------|---------|
| Total_bilirubin_upper_limit      | 35.41655389 | 3.31E-07|
| Platelet_result_lower_limit      | 1.070080085 | 0.006911203|
| Platelet_result_upper_limit      | 1.068948854 | 0.00341265|
| Platelet_result_count            | 1.051063842 | 0.059517343|
| Neoplasm_histologic_grade        | 1.250333525 | 0.127362381|
| Fetoprotein_outcome_value        | 0.977247772 | 0.162204753|
| Weight                           | 0.772356088 | 0.208050661|
| Age_at_initial_pathologic_diagnosis | 0.859880674 | 0.127362381|
| Sample_type                      | 0.47341456 | 0.456630015|
| Bilirubin_lower_limit            | 0.604438968 | 0.841065126|
| Gender                           | 0.936796253 | 0.67689342 |
| Bilirubin_upper_limit            | 0.964460012 | 0.854789298|
| Histological_type                | 0.859604808 | 0.854789298|

2.7. Analysis of Key Genes and Immunological Characteristics.
Analysis of TP53 mutation status (TP53 mutation status) and promoter methylation levels (promoter methylation) for normal data and hepatocellular carcinoma data was performed through the UALCAN website [20].

An immunization file on LIHC patients in TCGA was downloaded through the TIMER 2.0 website [21]. This file includes TIMER, CIBERSORT, quanTIseq, xCell, and MCP-counter [22–26]. Infiltration estimation of TCGA patients was performed with these 5 tools. RNA data were processed using the R package DESeq2 package [27], and the association between core genes and immunity was analyzed using the R package psyc. Finally, heat map presentation was performed by heatmap of R package.

2.8. Core Genes Targeting Corresponding Drug Candidates.
Interaction studies of obtained hub genes with relevant drugs were performed to analyze their targeting effects, where candidate antihepatocellular carcinoma drugs were
obtained from the DGIdb (http://www.dgidb.org/) database, an online tool containing information on drug-gene interactions from more than 30 libraries. These molecules were mainly from the ZINC library (https://zinc.docking.org/), while others were drawn by marvinsketch (version 21.9) [28], and the lowest energy conformation was selected. The conversion of mol2 files was performed using the open source chemistry toolbox open Babel (version 2.3.2) [29].

The 3D structures of the proteins expressed by the target genes were obtained from the RCSB PDB library (https://http://www.rcsb.org/). PyMOL (version 2.3) [30] removes hydrogen bonds and other ligands from the target protein. Autodocktools (version 1.5.6) [31] adds hydrogen atoms, binds nonpolar hydrogen atoms, calculates the charge number of the protein, and detects the docking sites. Finally, the target protein in pdbqt format is docked to the drug.

Figure 4: (a) Multivariate Cox regression forest map. (b) ROC curve used to evaluate prognosis model. (c) KM curve of total bilirubin upper limit. (d) KM curve of prognostic genes combined with landmark analysis.
candidate by AutoDock Vina 1.1.2 [32] with a threshold of affinity -7.0 kcal/mol. The final 2D structure is drawn using ligplot (version 4.0) [33].

3. Results

3.1. Analysis of Data in TCGA-LIHC Samples. After the differential analysis of TCGA-LIHC samples, 3529 differential lncRNAs, including 3008 upregulated genes and 521 downregulated genes, were screened; 2183 differential mRNAs, including 4074 upregulated genes and 1109 downregulated genes, were obtained; 330 differential genes of miRNAs, were obtained; 2183 differential mRNAs were HCC survival-related genes.

Next, GO and KEGG enrichment analyses were performed on the up- and downregulated differential mRNAs. We found that the expression of upregulated genes was mainly focused on the pathways with cell morphology, channels, and receptors. The downregulated differential genes, on the other hand, were mainly distributed in pathways related to metabolism and degradation (Figure 3). These changes may be related to disruption of liver function.

3.2. Cox Regression Analysis of Clinical Indicators. Cox regression analyses were performed on clinical data. The clinical information included fetoprotein outcome value, total bilirubin upper limit, bilirubin lower limit, bilirubin upper limit, age at initial pathologic diagnosis, sample type, gender, histological type, neoplasm histologic grade, platelet result count, platelet result lower limit, platelet result upper limit, and weight. The ROC curve and KM survival analysis combined with landmark analysis showed that the upper limit of total bilirubin could effectively distinguish between high-risk and low-risk patients with \( p = 0.0019 \) (Table 1, Figure 4). Methemoglobin is often used as a diagnostic indicator for HCC. Therefore, we selected age at initial pathologic diagnosis, bilirubin lower limit, bilirubin upper limit, survival time, fetoprotein outcome value, and total bilirubin upper limit as the clinical indicators associated with WGCNA.

3.3. WGCNA Expression Module Analysis. Initial screening using WGCNA selected \( \beta = 3 \) as the soft threshold of the network, and 21 gene coexpression modules were obtained by WGCNA (Table 2).

The correlation between modules and clinical characteristics was analyzed according to the clinical profile of UCSC Xena. Turquoise module was found to be highly correlated with survival time and survival status \( (p < 0.05) \). Also, the blue module was highly correlated with other clinical information (Figure 5(b)). The correlation between blue and turquoise modules was low (Figure 5(c)). And the topological overlap matrix (TOM) plot showed a strong coexpression relationship of genes in both modules (Figure 5(d)). Two coexpression modules were obtained, in which lncRNAs and mRNAs were HCC survival-related genes.

| Module       | Number |
|--------------|--------|
| Tan          | 55     |
| Black        | 115    |
| Blue         | 561    |
| Cyan         | 47     |
| Green yellow | 57     |
| Red          | 178    |
| Yellow       | 208    |
| Grey60       | 36     |
| Light green  | 36     |
| Light yellow | 33     |
| Royal Blue   | 32     |
| Light cyan   | 37     |
| Brown        | 409    |
| Magenta      | 84     |
| Salmon       | 49     |
| Green        | 181    |
| Purple       | 60     |
| Turquoise    | 3174   |
| Midnight blue| 45     |
| Pink         | 114    |
| Grey         | 989    |

3.4. PPI Network Construction and Core Gene Extraction. Based on MM values, 2000 genes of turquoise were analyzed by STRING. The degree values were visualized by Network Analyzer of Cytoscape software, and the eight genes with the most significant degree values were screened: PLK1, CDK1, CDC20, CCNB2, CCNB1, CCNA2, BUB1B, and BUB1 (Figure 7). Similarly, PPI analysis of genes from the blue module was performed to screen the six genes with the most significant degree values: CAT, ACADM, EHHADH,
3.5. Six Networks Were Constructed Based on ENCORI. A total of 114 genes were used in the turquoise module to construct the networks, including 106 genes screened in the turquoise module using $|MM| > 0.75$ as the criterion and 8 genes obtained by PPI analysis. Three turquoise-related networks were established: a lncRNA-miRNA-mRNA coexpression network consisting of 1 lncRNA, 8 miRNAs, and 10 mRNAs; a lncRNA-RBP-mRNA network consisting of 5 lncRNAs, 121 RNA binding proteins (RBPs), and 18 mRNAs; a RBP-mRNA-Tissue-Disease network consists of 104 RBPs, 13 mRNAs, 14 tissue, and 29 diseases (Figure 8).

A total of 128 genes from the blue module were used to construct the network, including 122 genes (106 lncRNAs and 112 mRNAs) screened by MM > 0.6 and 6 genes obtained by PPI analysis. Three turquoise-related networks were established: the lncRNA-miRNA-mRNA coexpression network consisted of 3 lncRNAs, 22 miRNAs, and 29 mRNAs; the lncRNA-RBP-mRNA network consisted of 4 lncRNAs, 128 RNA binding proteins (RBPs), and 112 mRNAs; the RBP-mRNA-Tissue-Disease network consisted of 48 RBPs, 9 mRNAs, 14 tissue, and 22 diseases (Figure 9).
Figure 6: (a) GO biological process (GO-BP) of turquoise modules. (b) GO cellular component (GO-CC) of turquoise modules. (c) GO molecular function (GO-MF) of turquoise modules. (d) KEGG pathway of turquoise modules. (e) GO-BP of blue modules. (f) GO-CC of blue modules. (g) GO-MF of blue modules. (h) KEGG pathway of blue modules.

Figure 7: (a) The PPI network diagram of the first 2000 genes of turquoise module. (b) The PPI network diagram of blue module. The darker the color and the larger the shape mean, the greater the degree contribution.
Figure 8: Network diagram of turquoise module with $|MM| > 0.75$ and its PPI hub gene; the darker the color, the larger the shape, representing a greater degree contribution. (a) Coexpression network of lncRNA-miRNA-mRNA: the hub lncRNA is SNHG1; the hub of miRNA is hsa-miR-3918; the hubs of mRNAs are MCM8 and PHF19. (b) lncRNA-RBP-mRNA network: the hub lncRNAs are SNHG1 and LENG8-AS1; the hub RBPs are SRSF1 and EIF4A3; the hub mRNAs are BUB1, RBL1, and KIF18B. (c) RBP-mRNA-Tissue-Disease network: hub RBPs are IGF2BP2 and EIF4A3; hub mRNAs are PLK1 and CDC20; hub organs are breast and liver; hub disease is carcinoma.

Figure 9: Network diagram of blue module with $|MM| > 0.6$ and its PPI hub gene; the darker the color, the larger the shape, representing a greater degree contribution. (a) Coexpression network of lncRNA-miRNA-mRNA: the hub lncRNAs are LINC00261 and DHRS4-AS1; the hubs of miRNAs are hsa-miR-1270 and hsa-miR-2278; the hub of mRNA is ATP11C. (b) lncRNA-RBP-mRNA network: the hub lncRNAs are LINC00261 and LINC01018; the hub RBPs are FUS and TAF15; the hub mRNAs are MTHFD1 and LARP1B. (c) RBP-mRNA-Tissue-Disease network: hub RBPs are EIF4A3 and IGF2BP2; hub mRNAs are MTHFD1 and AL139011.2; hub organs are breast and liver; hub disease is carcinoma.
3.6. The ROC Curves Showed the Good Performance of the Prognostic Model. Univariate Cox regression analysis was performed on mRNAs and lncRNAs in all differentially expressed genes, turquoise module, and blue module to explore their relationship with prognosis of hepatocellular carcinoma patients. Among all mRNAs, WISP3 ($p = 0.01$) and STK32B ($p = 0.022$) were screened. The AUC values of 3- and 5-year disease-free survival were 0.775 and 0.769, respectively. Among all lncRNAs, AL359853.1 ($p = 0.005$), AC110285.3 ($p = 0.025$), and FGF14-AS2 ($p = 0.013$) were screened. The AUC values of 3- and 5-year disease-free survival were 0.793 and 0.751, respectively. Among lncRNAs in the turquoise module, FGF14-AS2 ($p = 0.019$) was screened. The AUC values of 3- and 5-year disease-free survival were 0.699 and 0.67, respectively. Among mRNAs in the turquoise module, SOX11 ($p = 0.014$), HOXC8 ($p = 0.004$), GAGE2A ($p < 0.001$), and ETV4 ($p = 0.016$) were screened. The AUC values of 3- and 5-year disease-free survival were 0.85 and 0.801, respectively. Among mRNAs in the blue module, CISH ($p = 0.001$) was screened. The AUC values of 3- and 5-year disease-free survival were 0.826 and 0.834, respectively. The same survival analysis was performed for the core genes PLK1, CDK1, CDC20, CCNB2, CCNB1, CCNA2, BUB1B, and BUB1 of PPI in the turquoise module (Figure 10, Figure 11).

KM survival curves were used to observe the relationship between genes and survival. If the survival curves intersected, landmark analysis was performed. Finally, 11 prognosis-related genes were screened for the first time ($p < 0.01$): WISP3, STK32B, AL359853.1, AC110285.3, FGF14-AS2, HOXC8, GAGE2A, CDK1, CDC20, CCNA2, and BUB1. Higher levels of these genes were associated with poorer prognosis and may be poor prognostic liver cancer factors (Figure 12).

While landmark analysis showed that the higher expression levels of ETV4, SOX11, CCNB2, PLK1, BUB1B, and CCNB1 are the worse prognosis, which may be a poor prognostic factor for hepatocellular carcinoma, the higher expression levels of CISH are the better prognosis, which may be a protective factor for HCC prognosis (Figure 13).

3.7. GSEA Analysis Revealed 11 Genes Closely Associated with Cell Cycle and Translation. The median expression values of the survival genes screened were divided into two expression level groups. GSEA was then performed to detect the set of genes enriched in the gene classes of...
| Gene  | Hazard Ratio | 95% CI      | P-value |
|-------|--------------|-------------|---------|
| CBX2  | 0.231        | (0.94 – 1.3)| <0.01   |
| DCAF13| 0.354        | (0.86 – 1.5)| <0.01   |
| HSPA6 | 0.205        | (0.95 – 1.3)| <0.01   |
| MMP1  | 0.211        | (0.96 – 1.2)| <0.01   |
| SPTY2D1OS | 0.159    | (0.96 – 1.5)| <0.01   |
| STK32B| 0.022        | (1.04 – 1.6)| <0.01   |
| WISP3 | 0.739        | (0.77 – 1.5)| <0.01   |

# Events: 77; Global p-value (Log-Rank): 1.5548e–08
AIC: 694.08; Concordance Index: 0.73

---

| Gene  | Hazard Ratio | 95% CI      | P-value |
|-------|--------------|-------------|---------|
| AC068025.1| 0.509      | (0.86 – 1.3)| <0.01   |
| LINC01508 | 0.808      | (0.77 – 1.5)| <0.01   |
| AC110285.3 | 0.025      | (1.03 – 1.6)| <0.01   |
| AC124067.3 | 0.306      | (0.86 – 1.6)| <0.01   |
| AC124067.4 | 0.347      | (0.94 – 1.5)| <0.01   |
| AC124254.1 | 0.413      | (0.85 – 1.5)| <0.01   |
| AL359853.1 | 0.005      | (1.10 – 1.7)| <0.01   |
| AP003469.3 | 0.808      | (0.77 – 1.4)| <0.01   |
| FGFL4–AS2 | 0.013      | (1.05 – 1.5)| <0.01   |
| GSEC      | 0.157      | (0.93 – 1.6)| <0.01   |

# Events: 77; Global p-value (Log-Rank): 0.0012811
AIC: 720.06; Concordance index: 0.65

---

| Gene  | Hazard Ratio | 95% CI      | P-value |
|-------|--------------|-------------|---------|
| AC012485.2| 0.179      | (0.94 – 1.4)| <0.01   |
| AC015912.3 | 0.076      | (0.98 – 1.4)| <0.01   |
| AC078778.1 | 0.704      | (0.84 – 1.3)| <0.01   |
| AL359878.1 | 0.649      | (0.84 – 1.3)| <0.01   |
| ATP2A1–AS1 | 0.57       | (1.89 – 1.2)| <0.01   |
| FGF14–AS2 | 0.019      | (1.03 – 1.5)| <0.01   |

# Events: 77; Global p-value (Log-Rank): 8.45683708162e-06
AIC: 720.06; Concordance index: 0.65

---

**Figure 11: Continued.**
3.8. Five Machine Learning Models Demonstrated the Importance of 21 Genes in HCC. Gradient boosting, random forest, support vector machine, logistic regression, and integrated learning of data featuring 21 genes, which include the 15 survival-related mRNAs mentioned above and 6 PPI. The mRNAs belong to blue module are as follows: CAT, ACADM, EHHADH, AGXT, HMGCS2, and CYP3A4. The four models for judging HCC were finally generated through training, testing, and validation (Figure 15). The gradient boosting machine’s feature contribution degree bar graph showed that CCNB1, GAGE2A, and CYP3A4 were the more important features for judging HCC (Figure 15(c)). And the bar graph of feature contribution degree of random forest showed that CCNB1, BUB1, and both groups to identify their expression levels and pathway associations. In an analysis, mostly, genes were enriched in cell cycle and protein replication-related pathways (Figure 14), further suggesting that these genes proceed to be associated with survival.

Figure 11: Lasso and multiple Cox regression analysis results. Left: Cox regression analysis results forest map. Middle: ROC curve was used to evaluate the prognosis model. Right: KM curve of risk level. (a) All mRNA. (b) All lncRNA. (c) lncRNA of turquoise module. (d) mRNA of turquoise module. (e) mRNA of blue module.
CYP3A4 were the more important features for judging HCC (Figure 15(f)). In all metrics, random forest performed the best, and logistic regression was poor, but all these models reflected good training (Table 3). Therefore, we included them in the integrated learning, which uses a voting mechanism; if the voting ratio is 2:2, we use the value of random forest. Finally, the accuracy of the test set was improved to 0.97, the accuracy of the validation set was improved to 0.92, and other metrics were also improved (Table 3).

3.9. Key Genes Associated with TP53 Mutations, Promoter Methylation, and Immune Cell Infiltration. TP53 is a frequently mutated gene in many cancers. According to the analysis of the UALCAN database, among these genes in hepatocellular carcinoma, all genes were significantly

![Survival curves of various genes](image-url)
Figure 13: KM curve after Cox analysis (left). KM curve of prognostic gene after landmark analysis (right). (a) BUB1B. (b) PLK1. (c) SOX11. (d) ETV4. (e) CISH. (f) CCNB2. (g) CCNB1.
The methylation level of promoter region is closely related to tumor development. Therefore, we analyzed the methylation levels of the promoter regions of these core genes in hepatocellular carcinoma tissues. We found that the promoter methylation levels of CDK1, BUB1, ETV4, PLK1, WISP3, CCNB2, CISH, CCNB1, CCNA2, and GAGE2A were significantly decreased in hepatocellular carcinoma compared with normal tissues, while the promoter methylation levels of STK32B, SOX11, HOXC8, and BUB1B were significantly increased compared with normal tissues (Figure 17).

We analyzed the relationship between these core genes and immune cell infiltration through the TIMER 2.0 website. The heat map showed that all these genes were associated with immune cell infiltration and were mainly distributed on CD4 T cells, macrophage, regulatory T cells, and monocyte. As a whole, these genes clustered into two different parts, and their relationship with immune cell infiltration was almost completely opposite. The clustering results also showed that these genes could be divided into two clusters. The first cluster contains ACADM, AGXT, CAT, CISH, CYP3A4, EHHADH, FGF14-AS2, HMGCS2, and WISP3 genes, which are negatively associated with CD4 T cells, macrophages, and regulatory T cells, and positively associated with monocytes. Interestingly, in addition to the seven genes in the blue module, WISP3 and FGF14-AS2 in the turquoise module were also clustered in the first cluster and were clustered together. The second cluster is almost the exact opposite of the first cluster in terms of immune cell infiltration relationship (Figure 18). The correlation between them was further confirmed by the relationship map between genes (Figure 19).

KEGG pathway enrichment showed that the first cluster was mainly metabolism-related pathways, and since the previous machine learning results showed that CYP3A4 was an important feature-contributing gene in the hepatocellular carcinoma diagnostic model, we expanded the p adjust value to 0.56 to include linoleic acid metabolism (LAM) containing CYP3A4 as a pathway of interest, in addition to some pathways of metabolism, PPAR signaling pathway, and terpenoid backbone biosynthesis. In the second cluster, besides cell cycle-related pathways, progesterone-mediated oocyte maturation, p53 signaling pathway, FOXO signaling pathway, and immune abnormalities-related pathways were also enriched (Figure 20).

3.10. Screening and Molecular Docking of Four Gene Candidates. Proteins without structure in the RCSB PDB library were excluded. A total of 257 small molecules related to CCNA2, CCNB1, CDK1, and PLK1 with high feature contribution in machine learning were obtained by DGIdb online tool. The PDB structure 2IW8 for CCNA2, 4YC3 for CCNB1, 6GU6 for CDK1, and 3DB6 for PLK1 were obtained from the RCSB PDB library were obtained. Under the condition of docking affinity score greater than -7.0 kcal/mol, 8 small molecules were found to have high affinity with cyclin A2 expressed by CCNA2, 44 small molecules had high affinity with G2/mitotic-specific cyclin-B1 expressed by CCNB1, 184 small molecules had high affinity to CDK1-expressed cyclin-dependent kinase 1 (CDK1), and 191 small molecules had
Figure 15: (a) ROC curve of gradient boosting test set (AUC > 0.966). (b) ROC curve of gradient boosting verification set (AUC > 0.926). (c) The feature importance of gradient boosting training concentration. (d) ROC curve of random forest test set (AUC > 0.967). (e) ROC curve of random forest validation set (AUC > 0.937). (f) Characteristic importance of random forest training set. (g) ROC curve of support vector machine test set (AUC > 0.966). (h) ROC curve of support vector machine validation set (AUC > 0.948). (i) ROC curve of logistic regression test set (AUC > 0.927). (j) ROC curve of logistic regression validation set (AUC > 0.946).
Table 3: Training effects of five models: 0 is a normal sample, and 1 is a cancer sample.

| Model       | Set                                      | Indicators                                                                 |
|-------------|------------------------------------------|-----------------------------------------------------------------------------|
|             |                                          |                              | 5-fold cross-validation | 0.91397849 | 0.93548387 | 0.9673913 | 0.95652174 | 0.95652174 |
| Gradient boosting | Leave-one-out method                           |                              | Mean accuracy: 0.94          |            |            |            |            |            |
| Test set    |                                          | Precision | Recall | f1-score | Support | 0           | 0.88 | 0.85 | 0.86 | 26 |
|             |                                          |            |        |          |         | 1           | 0.96 | 0.97 | 0.96 | 90 |
|             |                                          | Accuracy   |          |          |         | 0.91 | 0.91 | 0.91 | 116 |
|             |                                          | Macro average |        |          |         | 0.92 | 0.91 | 0.91 | 116 |
|             |                                          | Weighted average |      |          |         | 0.94 | 0.94 | 0.94 | 116 |
|             |                                          | Precision | Recall | f1-score | Support | 0           | 0.88 | 0.89 | 0.88 | 105 |
|             |                                          |            |        |          |         | 1           | 0.92 | 0.91 | 0.92 | 152 |
|             |                                          | Accuracy   |          |          |         | 0.90 |          | 0.90 | 0.90 | 257 |
|             |                                          | Macro average |        |          |         | 0.90 | 0.90 | 0.90 | 257 |
|             |                                          | Weighted average |      |          |         | 0.90 | 0.90 | 0.90 | 257 |
|             |                                          |              |          |          |         |              |        |        |        |        |
|             | Validation set (default value) |                          |                              | 0.93548387 | 0.95698925 | 0.97826087 | 0.97826087 | 0.9673913 |
|             |                                          | Precision | Recall | f1-score | Support | 0           | 0.92 | 0.88 | 0.90 | 26 |
|             |                                          |            |        |          |         | 1           | 0.97 | 0.98 | 0.97 | 90 |
|             |                                          | Accuracy   |          |          |         | 0.96 |          | 0.96 | 0.96 | 116 |
|             |                                          | Macro average |        |          |         | 0.94 | 0.93 | 0.94 | 116 |
|             |                                          | Weighted average |      |          |         | 0.96 | 0.96 | 0.96 | 116 |
|             |                                          | Precision | Recall | f1-score | Support | 0           | 0.93 | 0.85 | 0.89 | 105 |
|             |                                          |            |        |          |         | 1           | 0.90 | 0.95 | 0.93 | 152 |
|             |                                          | Accuracy   |          |          |         | 0.91 |          | 0.91 | 0.91 | 257 |
|             |                                          | Macro average |        |          |         | 0.91 | 0.90 | 0.91 | 257 |
|             |                                          | Weighted average |      |          |         | 0.91 | 0.91 | 0.91 | 257 |
|             |                                          |              |          |          |         |              |        |        |        |        |
|             | Validation set (threshold = 0.4)            |                          |                              | 0.90322581 | 0.91397849 | 0.93478261 | 0.93478261 | 0.91304348 |
|             |                                          | Precision | Recall | f1-score | Support | 0           | 0.74 | 0.88 | 0.81 | 26 |
|             |                                          |            |        |          |         | 1           | 0.96 | 0.91 | 0.94 | 90 |
|             |                                          | Accuracy   |          |          |         | 0.91 |          | 0.91 | 0.91 | 116 |
|             |                                          | Macro average |        |          |         | 0.85 | 0.90 | 0.87 | 116 |
|             |                                          | Weighted average |      |          |         | 0.91 | 0.91 | 0.91 | 116 |
|             |                                          | Precision | Recall | f1-score | Support | 0           | 0.91 | 0.85 | 0.88 | 105 |
|             |                                          |            |        |          |         | 1           | 0.90 | 0.94 | 0.92 | 152 |
|             |                                          | Accuracy   |          |          |         | 0.90 |          | 0.90 | 0.90 | 257 |
|             |                                          | Macro average |        |          |         | 0.90 | 0.89 | 0.90 | 257 |
|             |                                          | Weighted average |      |          |         | 0.90 | 0.90 | 0.90 | 257 |

SVM

Test set

Accuracy

Macro average

Weighted average

Validation set (default value)

Accuracy

Macro average

Weighted average

Macro average

Weighted average
high affinity to PLK1-expressed polo-like kinase 1 (PLK1) (Table 4). Among them, ZINC40393428, ZINC3973984, and ZINC20149014 had high affinity in all four (Figure 21).

4. Discussion

HCC is a high mortality disease among cancers worldwide and has a poor prognosis. Not all patients are suitable for surgical treatment [34]. Alpha-fetoprotein (AFP) is a tumor marker secreted by different levels of hepatocellular carcinoma and therefore is often used as one of the few means to detect hepatocellular carcinoma [35]. However, some literature suggests that it is controversial [36–38]. Competitive binding to miRNA in lncRNA-miRNA-mRNA plays an important role in cancer development and regulation [39, 40]. We obtained turquoise and blue modules by WGCNA. Pathway analysis showed that the turquoise module is associated with cell cycle and DNA replication, and the blue module is mostly distributed in metabolism-related pathways. Accordingly, the ceRNA networks of both were constructed. Many of these genes have been shown to be associated with liver cancer. For example, in the turquoise module, the SNHG1 gene has been shown to be involved in cancer regulation, including hepatocellular carcinoma, through multiple ceRNA pathways [41]. The lncRNA-RBP-mRNA network was also constructed based on the theory that lncRNA recruitment of RBP affects mRNA [42]. Interestingly, SNHG1 was still included. We constructed an RBP-mRNA-Tissue-Disease network and showed that these combinations are frequently found in breast and liver and are mostly malignant epithelial tumors. Indeed, breast cancer has a very subtle relationship with the liver [43]. The results of our study also confirm the existence of this close relationship.

By univariate—Lasso—multiple Cox regression analysis and PPI, we obtained 11 genes according to survival time: WISP3, STK32B, AL359853.1, AC110285.3, FGF14-AS2, HOXC8, GAGE2A, CDK1, CDC20, CCNA2, and BUB1. These genes may be associated with prognostic relevance. WISP3 is a member of the CCN family, a family of cysteine-rich glycosylated proteins that are expressed in development and disease onset [44]. The results of our survival analysis were similar to other results where survival curves showed it to be a poor prognostic factor for hepatocellular carcinoma [45]. However, some studies have reported that WISP3 has the potential to inhibit the
development of hepatocellular carcinoma [46–48]. Indeed, the role of WISP3 seems to be different in different cancers [49], suggesting its complex regulatory mechanisms. STK32B is mainly associated with idiopathic tremor and anxiety [50, 51], but Parris et al. found that it may be a marker for oral squamous cell carcinoma [52]. AL359853.1, AC110285.3, and GAGE2 have also been noted to be possibly associated with the prognosis of HCC [53–55]. HOXC8 is a potential driver gene for many cancer cells and is associated with cell proliferation, adhesion, migration, and metabolism-related processes and can be considered as a global regulator of growth and differentiation [56–59]. FGF14-A52 has inhibitory effects on breast and colorectal cancers [60, 61] but has a promotive effect on gliomas [62], and its role in hepatocellular carcinoma has not been reported. CDK1 is required for mammalian cell proliferation. It is the only CDK that can initiate mitosis (i.e., M phase) [63], but tumor cells may also require specific interphase CDKs to proliferate. Therefore, selective CDK inhibition may provide therapeutic benefit in some human tumors [64]. CDC20 exerts its biological functions mainly by targeting its downstream substrates for ubiquitination and subsequent degradation [65] and plays a role in the cell cycle and apoptosis [66, 67]. In hepatocellular carcinoma, inhibition of CDC20 decreases cell proliferation in hepatocellular carcinoma cells [68]. CDC20 acts by various mechanisms, such as involvement in the p53-related pathway [69]. Ubiquitination of CCNA2 is associated with CDC20; the late promotion complex of ubiquitinated CCNA2 is activated by ubiquitination of CCNA2 is associated with CDC20; the late promotion complex of ubiquitinated CCNA2 is activated by the spindle assembly checkpoint is an important monitoring mechanism to ensure high-
and tried to improve the diagnosis rate by machine learning, survival time module and other modules with higher span model using the core genetic composition features of the learning to build a hepatocellular carcinoma discriminative diagnosis, we performed integrated enrichment results suggest that these genes are associated with APC-related processes, which may be key nodes in the progression and occurrence of hepatocellular carcinoma. GSEA

PLK1 is an known to promote cancer development. PLK1 is an ubiquitination-dependent pathway, and CCNB1 is also cyclin A and cyclin B are degraded by the proteasome through separation from CDK, and in the presence of APC, M phase G2 phase to mitosis. After mid mitosis, cell cycle proteins are

during the progression of hepatocellular carcinoma in

cellular or individual proteins that inhibit late promoting complex/loop (APC/C) ubiquitin ligase activity by targeting CDC20 regulatory subunits. BUB1 kinase is a key spindle checkpoint regulatory protein. BUB1 may promote proliferation of hepatocellular carcinoma cells by activating phosphorylation of SMAD2. Not surprisingly, among them, CDC20, CCNA2, and BUB1 are all associated with APC-related processes, which may be key nodes in the prognosis and occurrence of hepatocellular carcinoma. GSEA enrichment results suggest that these genes are associated with replication, translation, and chromosome formation.

To improve the accuracy and enrich the means of hepatocellular carcinoma diagnosis, we performed integrated learning to build a hepatocellular carcinoma discriminative model using the core genetic composition features of the survival time module and other modules with higher span and tried to improve the diagnosis rate by machine learning, and the results showed that our model had high accuracy and AUC value.

In general, predictions are mainly based on the compositional features of genes and metabolites. CCNB1 is the gene with a large feature contribution in the model. During cytokinesis, CCNB1 binds to CDK1 to transition the cell from G2 phase to mitosis. After mid mitosis, cell cycle proteins are separated from CDK, and in the presence of APC, M phase cyclin A and cyclin B are degraded by the proteasome through ubiquitination-dependent pathway, and CCNB1 is also known to promote cancer development. PLK1 is an inhibitor of the regulatory late promoting complex/cyclosome (APC/C) and can synergistically promote cell cycle protein B/Cdk1-mediated APC/C activation.

These related genes obtained by analysis of TP53 mutations, promoter methylation, and immune cell infiltration influence the progression of hepatocellular carcinoma in
these aspects. By looking at the clustering results from an immune perspective, it is easy to distinguish between the blue module and other genes outside of it. And the results of KEGG pathway analysis also suggest that these core genes are involved in some immune-related pathways.

Recent studies have shown that dysregulation of propanoate metabolism produces a prometastatic profile in breast and lung cancer cells, promoting cancer progression [78]. In contrast, linoleic acid and butyric acid have therapeutic potential for cancer, and they are both implicated...
in intestinal flora metabolism [79, 80], and intestinal flora and related metabolite molecules, which translocate through the portal vein to the liver and affect liver function, portend a potential pathway for intestinal flora to treat liver cancer. Peroxisome proliferator-activated receptor (PPAR) belongs to a class of nuclear hormone receptors activated by fatty acids and their derivatives, which have been shown to have cell cycle and metabolic regulatory effects. Some evidence suggests that it has a promotive effect on hepatocellular carcinoma and can be used as a target for drugs [81, 82].

Branch-chain amino acid metabolism is the most significant pathway obtained in the analysis, and studies have shown that the supplementation of valine, leucine, and isoleucine in branch-chain amino acids has a preventive effect on hepatocellular carcinoma [83]. In cluster II, in addition to the pathways of senescence and cell proliferation that often accompany cancer, we identified two interesting pathways—the progesterone-mediated oocyte maturation pathway and the oocyte meiotic pathway.

Although the role of progesterone-mediated oocyte maturation pathway and oocyte meiosis pathway in hepatocellular carcinoma is not clear, it has been reported in the literature that glioblastoma, lung cancer, etc. appear to be genetically enriched in these two pathways [84, 85]. Hepatocellular carcinoma is a sex-specific cancer, and in general, men are two to four times more likely to develop HCC than women [86], which predicts that some hormonal changes may contribute to this difference, among which progesterone receptor expression can affect the proliferation of hepatocellular carcinoma [87]. Enriched pathway, in which the FOXO transcription factor family plays an important role in tumor proliferation and apoptosis [88], FOXO1 was shown to play a repressive role in hepatocellular carcinoma [89], and other FOXO transcription factors have been shown to be associated with hepatocellular carcinoma [90, 91]. These evidences suggest that the genes we screened affect the progression of hepatocellular carcinoma by influencing the metabolic, immune, and other pathways.

Finally, we screened for potential drug candidates that might have an effect on HCC. To our surprise, many of these drugs have been found to have therapeutic effects on hepatocellular carcinoma, although the association with the genes we identified is not yet clear. For example, ZINC9566782 (hygromycin) has the highest docking affinity for cyclin A2. It suppresses stemness and malignancy of HCC cells by destroying CD133 in the L CSC population [92]. ZINC40393428 (SNS-314) has also been shown to be efficacious in hepatocellular carcinoma [93]. Our study provides recommendations for the diagnosis and treatment of hepatocellular carcinoma. However, due to the limitations of TCGA and GEO libraries, our results may need to be demonstrated by follow-up experiments.
Only a few machine learning algorithms are used in this study. In addition to the methods used in this paper, some of the most representative computational intelligence algorithms can be used to solve the problem, such as monarch butterfly optimization (MBO), earthworm optimization algorithm (EWA), elephant herding optimization (EHO), moth search (MS) algorithm, slime mold algorithm (SMA), hunger games search (HGS), Runge Kutta optimizer (RUN), colony predation algorithm (CPA), and Harris hawks optimization (HHO). These algorithms have the potential to provide better choices for our models. Many learning techniques have been developed to improve the performance of metaheuristic algorithms, such as the dynamic learning evolution algorithm (DLEA) [94] and the
Table 4: Docking results of four proteins with molecules in small molecule library (candidate drug list).

| Cyclin A2 Molecule | G2/mitotic-specific cyclin-B1 Affinity | Cyclin-dependent kinase 1 Affinity | Polo-like kinase 1 Affinity |
|--------------------|---------------------------------------|-----------------------------------|-----------------------------|
| ZINC95626782       | -7.6                                  | ZINC3817327                       | ZINC13597410                |
| ZINC9495236        | -7.6                                  | ZINC3979384                       | ZINC100461551               |
| ZINC1629864        | -7.4                                  | ZINC3814435                       | ZINC3939511                 |
| ZINC40393428       | -7.2                                  | ZINC5328058                       | ZINC35930738                |
| ZINC3817327        | -7.1                                  | ZINC3879185                       | ZINC23894                   |
| ZINC3973984        | -7                                    | ZINC3920266                       | ZINC1554646                 |
| ZINC14948097       | -7                                    | ZINC3861470                       | ZINC29053046                |
| ZINC20149014       | -7                                    | ZINC1554668                       | ZINC2109876                 |
| ZINC43154472       | -7.6                                  | ZINC3780893                       | ZINC3403722                 |
| ZINC100461551      | -7.5                                  | ZINC3817793                       | ZINC3939511                 |
| ZINC100001998      | -7.5                                  | ZINC43154472                      | ZINC259958                  |
| ZINC34285229       | -7.5                                  | ZINC3498894                       | ZINC35930738                |
| ZINC3986640        | -7.4                                  | ZINC34285229                      | ZINC5328058                 |
| ZINC35930738       | -7.4                                  | ZINC100001998                     | ZINC1621536                 |
| ZINC538152         | -7.3                                  | ZINC3872446                       | ZINC29053046                |
| ZINC3861600        | -7.3                                  | ZINC21673413                      | ZINC43196885                |
| ZINC13597410       | -7.3                                  | ZINC5765083                       | ZINC538152                  |
| ZINC34948944       | -7.4                                  | ZINC34894449                      | ZINC3817327                 |
| ZINC34128366       | -7.3                                  | ZINC34285233                      | ZINC49785138                |
| ZINC49785138       | -7.3                                  | ZINC3820327                       | ZINC3995991                 |
| ZINC3820327        | -7.3                                  | ZINC1639355                       | ZINC21983587                |
| ZINC1621536        | -7.2                                  | ZINC34894449                      | ZINC3817327                 |
| ZINC43196885       | -7.2                                  | ZINC49785138                      | ZINC3817793                 |
| ZINC3860715        | -7.2                                  | ZINC3954595                       | ZINC16052807                |
| ZINC8762246        | -7.2                                  | ZINC34948948                      | ZINC3830466                 |
| ZINC34285233       | -7.2                                  | ZINC3879185                       | ZINC49603227                |
| ZINC9073           | -7.2                                  | ZINC14945777                      | ZINC37868887                |
| ZINC4822288        | -7.2                                  | ZINC72107868                      | ZINC34154472                |
| ZINC2109876        | -7.2                                  | ZINC20149024                      | ZINC49785138                |
| ZINC21288966       | -7.2                                  | ZINC9073                          | ZINC20149014                |
| ZINC20533312       | -7.1                                  | ZINC21288966                      | ZINC3941269                 |
| ZINC34894449       | -7.1                                  | ZINC19632891                      | ZINC3986640                 |
| ZINC5765083        | -7.1                                  | ZINC4822288                       | ZINC13597410                |
| ZINC4543798        | -7.1                                  | ZINC100706870                     | ZINC3029819                 |
| ZINC12726300       | -7.1                                  | ZINC8681123                       | ZINC236195                  |
| ZINC1619592        | -7.1                                  | ZINC538152                        | ZINC602090                  |
| ZINC3939511        | -7.1                                  | ZINC1559601                       | ZINC34948948                |
| ZINC3941269        | -7.1                                  | ZINC5582530                       | ZINC100001998               |
| ZINC8829745        | -7.1                                  | ZINC21983587                      | ZINC1321831                 |
| ZINC4817100        | -7                                    | ZINC3815419                       | ZINC20533312                |
| ZINC40393428       | -7                                    | ZINC43196885                      | ZINC3920266                 |
| ZINC20149014       | -7                                    | ZINC9331709                       | ZINC1487934                 |
| ZINC169335484      | -7                                    | ZINC16052807                      | ZINC4822288                 |

24 Computational and Mathematical Methods in Medicine
| Cyclin A2 Molecule | G2/mitotic-specific cyclin-B1 Molecule | Cyclin-dependent kinase 1 Molecule | Polo-like kinase 1 Molecule |
|-------------------|----------------------------------------|----------------------------------|---------------------------|
|       Affinity    |                                       | Affinity                         | Affinity                  |
| ZINC1629864       | -8.5                                   | ZINC196663                       | -8.8                      |
| ZINC12726360      | -8.5                                   | ZINC599734                       | -8.8                      |
| ZINC1555803       | -8.5                                   | ZINC20149017                     | -8.8                      |
| ZINC1700953       | -8.5                                   | ZINC8762246                      | -8.8                      |
| ZINC20149017      | -8.5                                   | ZINC3973984                      | -8.8                      |
| ZINC16052674      | -8.4                                   | ZINC5328058                      | -8.8                      |
| ZINC13340605      | -8.4                                   | ZINC9495236                      | -8.8                      |
| ZINC16052857      | -8.4                                   | ZINC72107868                     | -8.8                      |
| ZINC1649340       | -8.4                                   | ZINC8829745                      | -8.8                      |
| ZINC1621536       | -8.4                                   | ZINC16052682                     | -8.7                      |
| ZINC1606505       | -8.4                                   | ZINC53119602                     | -8.7                      |
| ZINC49113058      | -8.4                                   | ZINC1629864                      | -8.7                      |
| ZINC25958         | -8.4                                   | ZINC100461551                    | -8.7                      |
| ZINC4016162       | -8.4                                   | ZINC100706870                    | -8.7                      |
| ZINC37868887      | -8.4                                   | ZINC4817100                      | -8.7                      |
| ZINC4475360       | -8.4                                   | ZINC5247757                      | -8.7                      |
| ZINC1689786       | -8.4                                   | ZINC8681123                      | -8.7                      |
| ZINC602192        | -8.4                                   | ZINC3842402                      | -8.6                      |
| ZINC12504456      | -8.4                                   | ZINC4015433                      | -8.6                      |
| ZINC3986640       | -8.4                                   | ZINC3814435                      | -8.6                      |
| ZINC6745792       | -8.4                                   | ZINC38698888                     | -8.6                      |
| ZINC340372        | -8.4                                   | ZINC9331709                      | -8.6                      |
| ZINC6514705       | -8.4                                   | ZINC18825330                     | -8.6                      |
| ZINC39001795      | -8.3                                   | ZINC1554668                      | -8.6                      |
| ZINC599734        | -8.3                                   | ZINC3873287                      | -8.6                      |
| ZINC4015433       | -8.3                                   | ZINC3798734                      | -8.6                      |
| ZINC2002752       | -8.3                                   | ZINC12726360                     | -8.6                      |
| ZINC1904          | -8.3                                   | ZINC2047389                      | -8.6                      |
| ZINC34638188      | -8.2                                   | ZINC3861633                      | -8.5                      |
| ZINC20533312      | -8.2                                   | ZINC1559601                      | -8.5                      |
| ZINC3029819       | -8.2                                   | ZINC5597201                      | -8.5                      |
| ZINC18825330      | -8.2                                   | ZINC4693574                      | -8.5                      |
| ZINC16052682      | -8.2                                   | ZINC75148                        | -8.5                      |
| ZINC1853550       | -8.2                                   | ZINC6514705                      | -8.5                      |
| ZINC608205        | -8.2                                   | ZINC5582530                      | -8.5                      |
| ZINC3938688       | -8.2                                   | ZINC3273193                      | -8.5                      |
| ZINC21486914      | -8.2                                   | ZINC16052857                     | -8.4                      |
| ZINC3873287       | -8.2                                   | ZINC16186602                     | -8.4                      |
| ZINC3995991       | -8.1                                   | ZINC1841840                      | -8.4                      |
| ZINC196663        | -8.1                                   | ZINC3356648                      | -8.4                      |
| ZINC17175232      | -8.1                                   | ZINC1687300                      | -8.4                      |
| ZINC4817100       | -8.1                                   | ZINC1687273                      | -8.4                      |
| ZINC3842402       | -8.1                                   | ZINC3988917                      | -8.4                      |
| ZINC1066512       | -8.1                                   | ZINC549484                       | -8.3                      |
| ZINC3973984       | -8.1                                   | ZINC3872446                      | -8.3                      |
| ZINC4907473       | -8.1                                   | ZINC4762361                      | -8.3                      |
| ZINC3988917       | -8.1                                   | ZINC19632891                     | -8.3                      |
| ZINC14963227      | -8.1                                   | ZINC41714                        | -8.3                      |
Table 4: Continued.

| Cyclin A2 Molecule | Affinity | G2/mitotic-specific cyclin-B1 Molecule | Affinity | Cyclin-dependent kinase 1 Molecule | Affinity | Polo-like kinase 1 Molecule | Affinity |
|--------------------|----------|----------------------------------------|----------|-----------------------------------|----------|----------------------------|----------|
| ZINC75148          | -8.1     | ZINC55760827                           | -8.3     |
| ZINC13130211       | -8.1     | ZINC386389                              | -8.2     |
| ZINC3816409        | -8       | ZINC23894                               | -8.2     |
| ZINC4976875        | -8       | ZINC5765083                             | -8.2     |
| ZINC1487934        | -8       | ZINC9073                                | -8.2     |
| ZINC584092         | -8       | ZINC678019                              | -8.2     |
| ZINC2509437        | -8       | ZINC13983251                            | -8.2     |
| ZINC1687300        | -8       | ZINC1619592                             | -8.2     |
| ZINC4822587        | -8       | ZINC4543798                             | -8.2     |
| ZINC2990483        | -8       | ZINC13340605                            | -8.1     |
| ZINC678019         | -8       | ZINC3815419                             | -8.1     |
| ZINC2047389        | -7.9     | ZINC34894449                            | -8.1     |
| ZINC3356648        | -7.9     | ZINC4016162                             | -8.1     |
| ZINC13121831       | -7.9     | ZINC21673413                            | -8.1     |
| ZINC37868756       | -7.9     | ZINC4475360                             | -8.1     |
| ZINC549484         | -7.9     | ZINC3830394                             | -8       |
| ZINC27999611       | -7.9     | ZINC4822587                             | -8       |
| ZINC1697899        | -7.9     | ZINC851497                              | -8       |
| ZINC1687273        | -7.8     | ZINC3816409                             | -8       |
| ZINC40393428       | -7.8     | ZINC95626782                            | -8       |
| ZINC3273193        | -7.8     | ZINC13986815                            | -8       |
| ZINC43131420       | -7.8     | ZINC584092                              | -8       |
| ZINC1670146        | -7.8     | ZINC3812869                             | -7.9     |
| ZINC4762361        | -7.8     | ZINC4903379                             | -7.9     |
| ZINC4543798        | -7.8     | ZINC155803                              | -7.9     |
| ZINC1530689        | -7.7     | ZINC602192                              | -7.9     |
| ZINC16052675       | -7.7     | ZINC1066512                             | -7.9     |
| ZINC4903379        | -7.7     | ZINC1473                                | -7.9     |
| ZINC43128366       | -7.7     | ZINC52509437                            | -7.9     |
| ZINC3886406        | -7.7     | ZINC3874317                             | -7.9     |
| ZINC16052718       | -7.7     | ZINC608205                              | -7.9     |
| ZINC3798734        | -7.7     | ZINC1904                                | -7.9     |
| ZINC8214597        | -7.7     | ZINC3873285                             | -7.9     |
| ZINC3814435        | -7.7     | ZINC2665575                             | -7.8     |
| ZINC1554390        | -7.7     | ZINC44953                               | -7.8     |
| ZINC386389         | -7.7     | ZINC1649340                             | -7.8     |
| ZINC1757986        | -7.6     | ZINC3860715                             | -7.8     |
| ZINC40442496       | -7.6     | ZINC3861470                             | -7.8     |
| ZINC3918156        | -7.6     | ZINC39001795                            | -7.8     |
| ZINC603047         | -7.6     | ZINC40442496                            | -7.8     |
| ZINC14806879       | -7.6     | ZINC3938688                             | -7.8     |
| ZINC340306         | -7.6     | ZINC603047                              | -7.8     |
| ZINC3874317        | -7.6     | ZINC1700953                             | -7.8     |
| ZINC2665575        | -7.6     | ZINC1606505                             | -7.8     |
| ZINC3775641        | -7.5     | Ebsselen                                | -7.8     |
| ZINC3878528        | -7.5     | ZINC14945777                            | -7.8     |
| ZINC294736         | -7.5     | ZINC3954595                             | -7.7     |
| ZINC13132551       | -7.5     | ZINC275332                              | -7.7     |
Table 4: Continued.

| Cyclin A2 Molecule | Affinity | G2/mitotic-specific cyclin-B1 Molecule | Affinity | Cyclin-dependent kinase 1 Molecule | Affinity | Polo-like kinase 1 Molecule | Affinity |
|--------------------|----------|---------------------------------------|----------|-----------------------------------|----------|-----------------------------|----------|
| ZINC4953           | -7.5     | ZINC3918156                           | -7.7     |
| ZINC38698888       | -7.5     | ZINC3950132                           | -7.7     |
| ZINC225430          | -7.5     | ZINC1639355                           | -7.7     |
| ZINC20149019        | -7.5     | ZINC20149024                          | -7.7     |
| ZINC3873285         | -7.5     | ZINC16933548                          | -7.7     |
| ZINC41714           | -7.4     | ZINC2139624                           | -7.6     |
| ZINC1473            | -7.4     | ZINC3780893                           | -7.6     |
| ZINC4693574         | -7.4     | ZINC14806879                          | -7.6     |
| ZINC13983251        | -7.4     | ZINC8214597                           | -7.6     |
| ZINC3950132         | -7.4     | ZINC3775641                           | -7.6     |
| ZINC4411063         | -7.4     | ZINC340306                            | -7.6     |
| ZINC233343          | -7.3     | ZINC225430                            | -7.6     |
| ZINC3830394         | -7.3     | ZINC1697899                           | -7.6     |
| Ebselen             | -7.3     | ZINC2002752                           | -7.5     |
| ZINC5247757         | -7.3     | ZINC4411063                           | -7.5     |
| ZINC3812869         | -7.3     | ZINC294736                            | -7.5     |
| ZINC1530968         | -7.3     | ZINC13130211                          | -7.5     |
| ZINC8035014         | -7.3     | ZINC237953                            | -7.5     |
| ZINC4707792         | -7.3     | ZINC43131420                          | -7.5     |
| ZINC1531764         | -7.2     | ZINC1722140                           | -7.5     |
| ZINC236195          | -7.2     | ZINC16052718                          | -7.5     |
| ZINC602090          | -7.2     | ZINC4707792                           | -7.5     |
| ZINC13514886        | -7.2     | ZINC643046                            | -7.5     |
| ZINC1722140         | -7.2     | ZINC20149019                          | -7.5     |
| ZINC16186602        | -7.2     | ZINC85534336                          | -7.5     |
| ZINC4009000         | -7.2     | ZINC3886406                           | -7.4     |
| ZINC64373300        | -7.2     | ZINC37868756                          | -7.4     |
| ZINC4183729         | -7.2     | ZINC1531764                           | -7.3     |
| ZINC2139624         | -7.2     | ZINC8035014                           | -7.3     |
| ZINC1619592         | -7.2     | ZINC21486914                          | -7.3     |
| ZINC137884          | -7.2     | ZINC1757986                           | -7.3     |
| ZINC9495236         | -7.1     | ZINC3942646                           | -7.3     |
| ZINC388510          | -7.1     | ZINC13132551                          | -7.3     |
| ZINC13571422        | -7.1     | ZINC12474579                          | -7.3     |
| ZINC237953          | -7       | ZINC3878528                           | -7.2     |
| ZINC100037272       | -7       | ZINC1530968                           | -7.2     |
| ZINC3942646         | -7       | ZINC1853550                           | -7.2     |
| ZINC1087483         | -7       | ZINC35930738                          | -7.2     |
| ZINC1615742         | -7       | ZINC900708                            | -7.2     |
| ZINC5328058         | -7       | ZINC1530689                           | -7.2     |

ZINC1689786         | -7.1     |
ZINC1670146         | -7.1     |
ZINC1934            | -7.1     |
ZINC100071772       | -7.1     |
ZINC3861600         | -7.1     |
ZINC4009000         | -7       |
ZINC1641089         | -7       |
learning-based intelligent optimization algorithm (LIOA) [95]. This may be another effective way to improve model performance, and we will consider them in our subsequent studies. In addition, some biological experiments are also worth drawing on to demonstrate the reliability of the model and the importance of biomarkers [96].

5. Conclusions

In conclusion, we screened 2 modules, 6 networks, and 24 genes for hepatocellular carcinoma. Five machine learning models were constructed and screened for drug candidates for the core genes. This suggests that hepatocarcinogenesis
is a dynamic network with multiple mechanisms. Treating only one pathway or one type of gene is not appropriate, especially since the liver is involved in various metabolic pathways. Combining dynamic therapies may be the hope for a complete cure of liver cancer in the future.

**Data Availability**

The datasets provided in this study can be found in an online repository (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE102079 https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga).

**Conflicts of Interest**

The authors declare that there is no conflict of interest regarding the publication of this paper.

**Acknowledgments**

This work was supported by the Chongqing Postgraduate Research Innovation Program (Project No. CYS21324) and the Natural Science Foundation of Chongqing (Project No. cstc2021jcyj-msxmX0834).

**References**

[1] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries," CA: a Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, 2018.

[2] S. Mittal and H. B. El-Serag, "Epidemiology of hepatocellular carcinoma: consider the population," Journal of Clinical Gastroenterology, vol. 47, Supplement 1, pp. S2–S6, 2013.

[3] A. Qi, D. Zhao, F. Yu et al., "Directional mutation and cross-over boosted art colony optimization with application to COVID-19 X-ray image segmentation," Computers in Biology and Medicine, vol. 148, article 105810, 2022.

[4] K. Hu, L. Zhao, S. Feng et al., "Colonrectal polyp region extraction using saliency detection network with neutrosophic enhancement," Computers in Biology and Medicine, vol. 147, article 105760, 2022.

[5] W. Wang and C. Wei, "Advances in the early diagnosis of hepatocellular carcinoma," Genes & diseases, vol. 7, no. 3, pp. 308–319, 2020.

[6] K. Yasaka, H. Akai, O. Abe, and S. Kiryu, "Deep learning with convolutional neural network for differentiation of liver masses at dynamic contrast-enhanced CT: a preliminary study," Radiology, vol. 286, no. 3, pp. 887–896, 2018.

[7] S. Ren, Q. Qi, S. Liu et al., "Preoperative prediction of pathological grading of hepatocellular carcinoma using machine learning-based ultrasomics: a multicenter study," European Journal of Radiology, vol. 143, article 109891, 2021.

[8] J. K. Heimbach, L. M. Kulik, R. S. Finn et al., "AASLD guidelines for the treatment of hepatocellular carcinoma," Hepatology, vol. 67, no. 1, pp. 358–380, 2018.

[9] X. Hu, R. Chen, Q. Wei, and X. Xu, "The Landscape of alpha fetoprotein in hepatocellular carcinoma: where are we?," International Journal of Biological Sciences, vol. 18, no. 2, pp. 536–551, 2020.

[10] T. Lee, P. A. Rawding, J. Bu et al., "Machine-learning-based clinical biomarker using cell-free DNA for hepatocellular carcinoma (HCC)," Cancers, vol. 14, no. 9, p. 2061, 2022.

[11] Z. Tang, F. Zhang, Y. Wang et al., "Diagnosis of hepatocellular carcinoma based on salivary protein glycopatterns and machine learning algorithms," Clinical Chemistry and Laboratory Medicine (CCLM), vol. 60, no. 12, pp. 1963–1973, 2022.

[12] J. Wang, S. Jain, D. Chen, W. Song, C. T. Hu, and Y. H. Su, “Development and evaluation of novel statistical methods in urine biomarker-based hepatocellular carcinoma screening,” Scientific Reports, vol. 8, no. 1, article 3799, 2018.

[13] X. Li and C.-Y. Wang, “From bulk, single-cell to spatial RNA sequencing,” International Journal of Oral Science, vol. 13, no. 1, article 36, 2021.

[14] M. Du, N. Liu, and X. Hu, “Techniques for interpretable machine learning,” Communications of the ACM, vol. 63, no. 1, pp. 68–77, 2019.

[15] A. Maertens, V. Tran, A. Kleensang, and T. Hartung, "Weighted gene correlation network analysis (WGCNA) reveals novel transcription factors associated with bisphenol a dose-response," Frontiers in Genetics, vol. 9, pp. 508–508, 2018.

[16] X. Qi, D.-H. Zhang, N. Wu, J. H. Xiao, X. Wang, and W. Ma, "ceRNA in cancer: possible functions and clinical implications," Journal of Medical Genetics, vol. 52, no. 10, pp. 710–718, 2015.

[17] G. Yu, L.-G. Wang, Y. Han, and Q.-Y. He, "clusterProfiler: an R package for comparing biological themes among gene clusters," Omics : a journal of integrative biology, vol. 16, no. 5, pp. 284–287, 2012.

[18] A. Subramanian, P. Tamayo, V. K. Mootha et al., "Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles," Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 43, pp. 15545–15550, 2005.

[19] F. Pedregosa, G. Varoquaux, A. Gramfort et al., "Scikit-learn: machine learning in python," the journal of machine Learning research, vol. 12, pp. 2825–2830, 2011.

[20] D. S. Chandrashekar, B. Bashel, S. A. H. Balasubramanya et al., "UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses," Neoplasia, vol. 19, no. 8, pp. 649–658, 2017.

[21] T. Li, J. Fu, Z. Zeng et al., "TIMER2.0 for analysis of tumor-infiltrating immune cells," Nucleic Acids Research, vol. 48, no. W1, pp. W509–W514, 2020.

[22] B. Li, E. Severson, J.-C. Pignon et al., "Comprehensive analyses of tumor immunity: implications for cancer immunotherapy," Genome Biology, vol. 17, no. 1, pp. 174–174, 2016.

[23] F. Finotello, C. Mayer, C. Plattner et al., "Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data," Genome Medicine, vol. 11, no. 1, pp. 34–34, 2019.

[24] D. Aran, Z. Hu, and A. J. Butte, "xCell: digitally portraying the tissue cellular heterogeneity landscape," Genome Biology, vol. 18, no. 1, pp. 220–220, 2017.

[25] E. Becht, N. A. Giraltado, L. Lacroix et al., "Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression," Genome Biology, vol. 17, no. 1, pp. 218–218, 2016.
[26] M. I. Love, W. Huber, and S. Anders, “Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2,” *Genome Biology*, vol. 15, no. 12, pp. 550–550, 2014.

[27] J. A. S. Quaresma, G. T. Yoshikawa, R. V. L. Koyama, G. Dias, S. Fujihara, and H. Fuzi, “HTLV-1, immune response and autoimmunity,” *Viruses*, vol. 8, no. 1, p. 5, 2016.

[28] ChemAxon, “MarvinSketch,” https://www.chemaxon.com/products/marvin (May 2021).

[29] N. M. O’Boyle, M. Banck, C. A. James, C. Morley, T. Vandermeersch, and G. R. Hutchison, “Open babel: an open chemical toolbox,” *Journal of Chemicalinformatics*, vol. 3, no. 1, article 33, 2011.

[30] W. L. DeLano, “Pymol: an open-source molecular graphics tool,” *CCP4 Newsl. Protein Crystallogr.*, vol. 40, no. 1, pp. 82–92, 2002.

[31] N. El-Hachem, B. Haibe-Kains, A. Khalil, F. H. Kobiessy, and G. Nemer, “AutoDock and AutoDockTools for protein-ligand docking: beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a case study,” in *Methods in Molecular Biology*, vol. 1598, pp. 391–403, Humana Press, New York, NY, 2017.

[32] O. Trott and A. J. Olson, “AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multi-threading,” *Journal of Computational Chemistry*, vol. 31, no. 2, pp. 455–461, 2010.

[33] A. C. Wallace, R. A. Laskowski, and J. M. Thornton, “LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions,” *Protein Engineering*, vol. 8, no. 2, pp. 127–134, 1995.

[34] S. T. Orcutt and D. A. Anaya, “Liver resection and surgical strategies for management of primary liver cancer,” *Cancer control: journal of the Moffitt Cancer Center*, vol. 25, no. 1, pp. 1073274817744621–1073274817744621, 2018.

[35] Y. Zheng, M. Zhu, and M. Li, “Effects of alpha-fetoprotein on the occurrence and progression of hepatocellular carcinoma,” *Journal of Cancer Research and Clinical Oncology*, vol. 146, no. 10, pp. 2439–2446, 2020.

[36] S. Gupta, S. Bent, and J. Kohlweis, “Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C: A systematic review and critical analysis,” *Annals of Internal Medicine*, vol. 139, no. 1, pp. 46–50, 2003.

[37] A. Colli, M. Fraquelli, and D. Conte, “Alpha-fetoprotein and hepatocellular carcinoma,” *American Journal of Gastroenterology*, vol. 101, no. 8, pp. 1939; author reply 1940–1949; author reply 1941, 2006.

[38] P. Luo, S. Wu, Y. Yu et al., “Current status and perspective biomarkers in AFP negative HCC: towards screening for and diagnosing hepatocellular carcinoma at an earlier stage,” *Pathology & Oncology Research*, vol. 26, no. 2, pp. 599–603, 2020.

[39] E. A. Braga, M. V. Fridman, A. A. Moscovtsev, E. A. Filippova, A. A. Dmitriev, and N. E. Kushinskii, “IncRNAs in ovarian cancer progression, metastasis, and main pathways: ceRNA and alternative mechanisms,” *International Journal of Molecular Sciences*, vol. 21, no. 22, p. 8855, 2020.

[40] X. Zeng, J. Xiao, X. Bai et al., “Research progress on the circRNA/incRNA-miRNA-miRNA axis in gastric cancer,” *Pathology-Research and Practice*, vol. 238, article 154030, 2022.

[41] S. Chen and X. Shen, “Long noncoding RNAs: functions and mechanisms in colon cancer,” *Molecular Cancer*, vol. 19, no. 1, pp. 167–167, 2020.

[42] L. Zhang, Z. Yang, J. Trottier, O. Barbier, and L. Wang, “Long noncoding RNA MEG3 induces cholestatic liver injury by interaction with PTBP1 to facilitate shp mRNA decay,” *Hepatology*, vol. 65, no. 2, pp. 604–615, 2017.

[43] J. R. Diamond, C. A. Finlayson, and V. F. Borjes, “Hepatic complications of breast cancer,” *The Lancet. Oncology*, vol. 10, no. 6, pp. 615–621, 2009.

[44] Y. Nakamura, G. Weidinger, J. O. Liang et al., “The CCN family member Wisp3, mutant in progressive pseudohematoïd dysplasia, modulates BMP and Wnt signaling,” *The Journal of Clinical Investigation*, vol. 117, no. 10, pp. 3075–3086, 2007.

[45] Q. Jia, B. Xu, Y. Zhang, A. Ali, and X. Liao, “CCN family proteins in cancer: insight into their structures and coordination role in tumor microenvironment,” *Frontiers in Genetics*, vol. 12, pp. 649387–649387, 2021.

[46] Y. Lu, X. Wang, X. Sun et al., “WISP3 is highly expressed in a subset of colorectal carcinomas with a better prognosis,” *Oncotargets and Therapy*, vol. 9, pp. 287–293, 2016.

[47] H. Gao, F.-F. Yin, D.-X. Guan et al., “Liver cancer: WISP3 suppresses hepatocellular carcinoma progression by negative regulation of β-catenin/TCF/LEF signalling,” *Cell Proliferation*, vol. 52, no. 3, pp. e12583–e12583, 2019.

[48] C. G. Kleer, Y. Zhang, Q. Pan et al., “WISP3 is a novel tumor suppressor gene of inflammatory breast cancer,” *Oncogene*, vol. 21, no. 20, pp. 3172–3180, 2002.

[49] J. Zeng, Y. Liao, J. Zhou, G. Yang, K. Ding, and X. Zhang, “Role of WISP3 siRNA in proliferation, apoptosis and invasion of bladder cancer cells,” *International Journal of Clinical and Experimental Medicine*, vol. 8, no. 8, pp. 12792–12800, 2015.

[50] C. Liao, F. Sarayloo, V. Vuokila et al., “Transcriptomic changes resulting from STK32B overexpression identify pathways potentially relevant to essential tremor,” *Frontiers in Genetics*, vol. 11, pp. 813–813, 2020.

[51] D. M. Cánculete, A. E. Boström, A. K. Tuunainen et al., “Changes in methylation within the STK32B promoter are associated with an increased risk for generalized anxiety disorder in adolescents,” *Journal of Psychiatric Research*, vol. 102, pp. 44–51, 2018.

[52] T. Z. Parris, L. Aziz, A. Kovács et al., “Clinical relevance of breast cancer-related genes as potential biomarkers for oral squamous cell carcinoma,” *BMC Cancer*, vol. 14, no. 1, article 324, 2014.

[53] J. Ye, S. Wu, S. Pan, J. Huang, and L. Ge, “Risk scoring based on expression of long non-coding RNAs can effectively predict survival in hepatocellular carcinoma patients with or without fibrosis,” *Oncology Reports*, vol. 43, no. 5, pp. 1451–1466, 2020.

[54] K. Ren, J. Ma, B. Zhou et al., “Identification of prognostic and immune-related lncRNAs in hepatocellular carcinoma based on the cancer genome atlas data mining,” *Materials Express*, vol. 10, no. 8, pp. 1189–1196, 2020.

[55] L. Shi, X. Shang, K. Nie et al., “Identification of potential crucial genes associated with the pathogenesis and prognosis of liver hepatocellular carcinoma,” *Journal of Clinical Pathology*, vol. 74, no. 8, pp. 504–512, 2021.

[56] H. Lei, H. Wang, A. H. Juan, and F. H. Ruddle, “The identification of HOXC8 target genes,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, no. 7, pp. 2420–2424, 2005.

[57] S. Lu, R. Liu, M. Su et al., “Overexpression of HOXC8 is associated with poor prognosis in epithelial ovarian cancer,” *Reproductive sciences*, vol. 23, no. 7, pp. 944–954, 2016.
R. Wolthuis, L. Clay-Farrace, W. van Zon et al., "HOXC8 promotes proliferation and migration through transcriptional up-regulation of TGFβ1 in non-small cell lung cancer," Oncogene, vol. 7, no. 2, pp. 1–1, 2018.

Y. Zhang, C. Yang, M. Zhang et al., "Interleukin enhancer-binding factor 3 and HOXC8 co-activate cadherin 11 transcription to promote breast cancer cells proliferation and migration," Oncotarget, vol. 8, no. 64, pp. 107477–107491, 2017.

Y. Yang, N. Xun, and J. Wu, "Long non-coding RNA FGF14-A52 represses proliferation, migration, invasion, and induces apoptosis in breast cancer by sponging miR-205-5p," European Review for Medical and Pharmacological Sciences, vol. 23, no. 16, pp. 6971–6982, 2019.

R. Hou, Y. Liu, Y. Su, and Z. Shu, "Overexpression of long non-coding RNA FGF14-A52 inhibits colorectal cancer proliferation via the RERG/Ras/ERK signaling by sponging microRNA-1288-3p," Pathology & Oncology Research, vol. 26, no. 4, pp. 2659–2667, 2020.

P. Zhang, X. Gu, N. Zhang et al., "FGF14-A52 accelerates tumorigenesis in glioma by forming a feedback loop with miR-320a/E2F1 axis," Journal of Cancer, vol. 12, no. 21, pp. 6429–6438, 2021.

U. Asghar, A. K. Witkiewicz, N. C. Turner, and E. S. Knudsen, "The history and future of targeting cyclin-dependent kinases in cancer therapy," Nature Reviews. Drug Discovery, vol. 14, no. 2, pp. 130–146, 2015.

M. Malumbres and M. Barbacid, "Cell cycle, CDKs and cancer: a changing paradigm," Nature Reviews. Cancer, vol. 9, no. 3, pp. 153–166, 2009.

M. D. J. Gurden, A. J. Holland, W. van Zon et al., "CDC20 is required for the post-anaphase, KEN-dependent degradation of centromere protein F," Journal of Cell Science, vol. 123, no. 3, pp. 321–330, 2010.

M. E. Harley, L. A. Allan, H. S. Sanderson, and P. R. Clarke, "Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its CDC20-dependent destruction during mitotic arrest," The EMBO Journal, vol. 29, no. 14, pp. 2407–2420, 2010.

H. J. Cho, E. H. Lee, S. H. Han et al., "Degradation of human RAP80 is cell cycle regulated by Cdc20 and Cdh1 ubiquitin ligases," Molecular Cancer Research, vol. 10, no. 5, pp. 615–625, 2012.

J. Li, J.-Z. Gao, J.-L. Du, Z.-X. Huang, and L.-X. Wei, "Increased CDC20 expression is associated with development and progression of hepatocellular carcinoma," International Journal of Oncology, vol. 45, no. 4, pp. 1547–1555, 2014.

S. Zhao, Y. Zhang, X. Lu et al., "CDC20 regulates the cell proliferation and radiosensitivity of P53 mutant HCC cells through the Bcl-2/Bax pathway," International Journal of Biological Sciences, vol. 17, no. 13, pp. 3608–3621, 2021.

R. Wolthuis, L. Clay-Farrace, W. van Zon et al., "Cdc20 and Cks direct the spindle checkpoint-independent destruction of cyclin A," Molecular Cell, vol. 30, no. 3, pp. 290–302, 2008.

H. Fu, Y. Zhang, Y. Chen, J. Chen, and P. Chen, "CSN1 facilitates proliferation and migration of hepatocellular carcinoma cells by upregulating cyclin A2 expression," Molecular Medicine Reports, vol. 23, no. 1, pp. 1, 2021.

T. Otto and P. Sicinski, "Cell cycle proteins as promising targets in cancer therapy," Nature Reviews. Cancer, vol. 17, no. 2, pp. 93–115, 2017.
[99] H.-C. Chi, S.-L. Chen, Y.-H. Cheng et al., “Chemotherapy resistance and metastasis-promoting effects of thyroid hormone in hepatocarcinoma cells are mediated by suppression of FoxO1 and Bim pathway,” Cell Death & Disease, vol. 7, no. 8, pp. e2324–e2324, 2016.

[100] J. Luo, A. Liang, M. Liang et al., “Serum glucocorticoid-regulated kinase 1 blocks CKD-induced muscle wasting via inactivation of FoxO3a and Smad2/3,” Journal of the American Society of Nephrology: JASN, vol. 27, no. 9, pp. 2797–2808, 2016.

[101] Q. Li, C. Gao, H. Deng, Q. Song, and L. Yuan, “Benzopyrene induces pyroptotic and autophagic death through inhibiting PI3K/Akt signaling pathway in HL-7702 human normal liver cells,” The Journal of Toxicological Sciences, vol. 44, no. 2, pp. 121–131, 2019.

[102] Y. Song, I.-K. Kim, I. Choi, S.-H. Kim, and H. R. Seo, “Oxytetracycline have the therapeutic efficiency in CD133+ HCC population through suppression CD133 expression by decreasing of protein stability of CD133,” Scientific Reports, vol. 8, no. 1, pp. 16100–16100, 2018.

[103] F. Liu, G. Wang, X. Wang et al., “Targeting high Aurora kinases expression as an innovative therapy for hepatocellular carcinoma,” Oncotarget, vol. 8, no. 17, pp. 27953–27965, 2017.

[104] W. Li, G.-G. Wang, and A. H. Gandomi, “A survey of learning-based intelligent optimization algorithms,” Archives of Computational Methods in Engineering, vol. 28, no. 5, pp. 3781–3799, 2021.

[105] G. Li, G.-G. Wang, J. Dong, W.-C. Yeh, and K. Li, “DLEA: a dynamic learning evolution algorithm for many-objective optimization,” Information Sciences, vol. 574, pp. 567–589, 2021.

[106] F. Capone, E. Guerriero, A. Sorice et al., “Synergistic antitumor effect of doxorubicin and tacrolimus (FK506) on hepatocellular carcinoma cell lines,” The Scientific World Journal, vol. 2014, Article ID 450390, 9 pages, 2014.